Business Wire

Haga Hospital in the Netherlands to Install State-of-the-Art MRI Ablation Center

Share

Imricor announced today that they have signed a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit an MRI ablation center for treating cardiac arrhythmias.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190508005217/en/

F.L.T.R. sitting: Karel Ronday, Director of Medical Affairs Haga Hospital and Steve Wedan, CEO of Im ...

F.L.T.R. sitting: Karel Ronday, Director of Medical Affairs Haga Hospital and Steve Wedan, CEO of Imricor Medical Systems F.L.T.R. standing: Cardiologist Hemanth Ramanna; Cardiologist Ivo van der Bilt; Cardiologist Vincent van Driel; Director of Sales Imricor Greg Englehardt; Not pictured: Manager Haga Heart Center Edith Bense (Photo: Business Wire)

This advanced MRI ablation center will contain a 1.5T MRI scanner and Imricor’s Advantage-MRTM EP Recorder/Stimulator System. This installation will establish the Haga Hospital and Heart Center as a world leader in the field of interventional cardiac magnetic resonance (iCMR) and place them among the first heart centers in the world to clinically adopt MRI-guided cardiac ablations.

“At the Haga MRI ablation center, we will be focusing on treating patients with arrhythmias with a more focused individualized ablation treatment plan. Performing the ablation in the MRI will give us the ability to adjust to each individual patient and allow us to make and assess the ablation lesion,” said Dr. Vincent van Driel, Director of Electrophysiology at the Haga Heart Center. “This project has been the most collaborative effort between 3 entities (hospital, physicians and industry) that I have ever been a part of. The willingness to work together is one key reason why this is becoming possible here at Haga Hospital.”

“Establishing the MRI ablation center at Haga Hospital marks an important milestone for the field of iCMR and, of course, for Imricor,” said Steve Wedan, Imricor’s CEO. “Haga is the first non-university hospital to make the move toward MRI guided ablations, and we feel that delivers a strong statement in support of this exciting field. We continue to be humbled by the extraordinary caliber of the medical leaders we get to work with, and we are so proud to be partnered with everyone at Haga Hospital.”

Cardiac procedures guided by MRI provide physicians with sophisticated soft tissue visualization that allows them to individualize treatment strategies for each patient’s unique cardiac structure and substrate as well as assess changes in tissue characteristics immediately post ablation. These benefits have the potential to improve patient outcomes and provide safer, more cost-effective treatment – all in an environment that is free of radiation for both the patient and physician.

About Imricor

Imricor Medical Systems is a privately held company committed to unlocking the potential of interventional cardiac magnetic resonance (iCMR) by delivering MR-compatible systems and devices that allow physicians to perform cardiac ablations under real-time MRI-guidance.

About Haga Hospital

The Haga Teaching Hospital is a large top clinical hospital in The Hague region. The Hospital is specialized in Heart care and surgery with one of the best results in terms of health outcomes in the country. The hospital also offers pediatrics in the Juliana Child Hospital, which is part of the hospital. It is one of the largest and most modern Accident and Emergency Departments in the region for adults and children.

CAUTION: The Advantage-MRTM EP Recorder/Stimulator System has received CE mark approval; it has not yet been approved for use in the United States. The Vision-MRTM Ablation Catheter has been approved as an investigational device for clinical studies in Europe. All other Imricor devices are not yet approved for use in humans.

Contact information

Steve Wedan - Imricor
+1 952.818.8417; info@imricor.com
www.imricor.com

Elly van Schaik
+31 06-22748796; E.vSchaik@hagaziekenhuis.nl
https://www.hagaziekenhuis.nl

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Velodyne Files Patent Infringement Complaint with ITC Against Hesai and RoboSense16.8.2019 15:00:00 EESTPress release

Velodyne Lidar, Inc. filed a patent infringement complaint with the U.S. International Trade Commission (ITC) against Hesai Photonics Technology Co., Ltd. and Suteng Innovation Technology Co., Ltd. (a.k.a. RoboSense) for violations of section 337 of the Tariff Act of 1930 which makes unfair methods of competition and importation of certain products into the United States unlawful. Earlier this week, Velodyne also filed patent infringement complaints against Hesai and RoboSense in the U.S. District Court for the Northern District of California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005041/en/ Velodyne Lidar’s Alpha Puck™, Ultra Puck™ and Puck™ surround view sensors (left to right). (Photo: Business Wire) Velodyne is asking the ITC to investigate these lidar manufacturers for unlawfully importing and selling lidar sensors that infringe Velodyne’s patented lidar technology (U.S. Patent 7,969,558). Velodyne reques

Merz Announces Key Governance Changes16.8.2019 12:26:00 EESTPress release

Merz, a global leader in medical aesthetics and specialty neurology, announced today that Philip Burchard will be appointed Chairman of the company’s Shareholders Council. He will assume this role in addition to his current position as Chief Executive Officer of the Merz Healthcare Group. In his new position, Philip Burchard will succeed Andreas Krebs, who has decided to step down from his current roles as Chairman of the Shareholders Council and Supervisory Board of Merz in order to dedicate more time to his personal entrepreneurial and philanthropic activities. In addition, Dr. Christian Holzherr will be the new Chairman of the Merz Supervisory Board. All changes will be effective as of October 31, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005106/en/ Philip Burchard, CEO of Merz (Photo: Business Wire) Philip Burchard joined Merz as CEO in July 2012. Under his leadership, Merz has focused its strategy on ae

FINEOS lists on the Australian Securities Exchange16.8.2019 10:22:00 EESTPress release

FINEOS Corporation Holdings plc (ASX:FCL), a leading provider of group and individual core systems for life, accident and health insurance, today announced the commencement of trading on the Australian Securities Exchange (ASX) via an initial public offering (IPO). The total number of securities (CHESS Depository Interests or “CDIs”) on offer was 84.4 million at a price of A$2.50 per CDI. Total gross proceeds from the offer amounted to A$211 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005058/en/ FINEOS lists on the Australian Securities Exchange (Photo: Business Wire) FINEOS intends to use the net proceeds from the IPO to invest further in R&D to grow the FINEOS product footprint and develop new business lines, to invest in additional sales, marketing and client account management capabilities and to pay down existing debt and shareholders selling down. Key areas of growth strategy for FINEOS include: • Inc

European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis15.8.2019 23:01:00 EESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190815005605/en/ “We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis and other inflammatory conditions,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. The MAA for filgotinib is supported by 24-week data from the Phase 3 FINCH clinical trials in which once-daily treatment with filgotinib achieved improvements in clinical signs and symptoms, achievem

Celsius Network Partners With Bitcoin.com15.8.2019 17:55:00 EESTPress release

Celsius Network, the industry-leading cryptocurrency platform, has announced a new partnership with Bitcoin.com, the leading resource for Bitcoin trading, news, and updates. Users of Celsius services are now able to purchase BCH, BTC, ETH, and other mutually supported cryptocurrencies through the Celsius app using Bitcoin.com’s advanced crypto trading platform providing low fees, enhanced accessibility to cryptocurrency, and valuable crypto services. With the shared mission of making financial services fair, rewarding, and transparent, Celsius and Bitcoin.com are well-known in the space for offering inclusive services designed to support the needs and interests of their robust communities. Celsius members can earn interest income of up to 10.53% APR on crypto assets and use their coins as collateral to get dollar loans at rates as low as 4.95% without fees or penalties, no minimums or caps, and no lockups. Bitcoin.com makes it easy to buy dozens of crypto assets instantly and without f

Anesthesia Patient Safety Foundation and Patient Safety Movement Foundation Offer $100,000 Patient Safety Curriculum Award15.8.2019 15:58:00 EESTPress release

The Anesthesia Patient Safety Foundation (APSF), in partnership with the Patient Safety Movement Foundation (PSMF), is now accepting proposals for the Patient Safety Curriculum Award. The $100,000 award will go to an anesthesia education investigator with the intent to modify the PSMF Patient Safety Curriculum to address perioperative patient safety. The awardee will also test the educational efficiency and effectiveness of implementing the curriculum in anesthesia training programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190815005377/en/ Anesthesia Patient Safety Foundation and Patient Safety Movement Foundation Offer $100,000 Patient Safety Curriculum Award (Graphic: Business Wire) “This important work will add to the considerable value provided by PSMF’s Patient Safety Curriculum,” said Mark Warner, APSF President. “To ensure the safety of patients and achieve our collective goal of zero preventable deaths in hosp

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom